References
- Theofilopoulos A N, Dixon F J. Autoimmune diseases. Immunopathology and etiopathogenesis. Am J Pathol 1982; 108: 321–65
- Theofilopoulos A N, Dixon F J. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269–390
- Kasahara K, Kobayashi K, Shikama Y, Yoneya I, Soezima K, Ide H, Takahashi T. Direct evidence for granuloma-inducing activity of interleukin-1: induction of experimental pulmonary granuloma formation in mice by interleukin-1-coupled beads. Am J Pathol 1988; 130: 629–38
- Kasahara K, Kobayashi K, Shikama Y, Yoneya I, Kaga S, Hashimoto M, Odagiri T, Soejima K, Ide H, Takahashi T, Yoshida T. The role of monokines in granuloma formation in mice: The ability of interleukin-1 and tumor necrosis factor-α to induce lung granulomas. Clin Immunol Immunopathol 1989; 51: 419–25
- Kobayashi K, Kasama T, Fukushima T, Kasahara K, Tabata M, Sekine F, Negishi M, Ide H, Takahashi T. Deficiency of interleukin 2 inhibitor activity in serum from autoimmune-prone mice. Immunol Invest 1987; 16: 45–55
- Fukushima T, Kobayashi K, Kasama T, Kasahara K, Tabata M, Sekine F, Negishi M, Ide H, Takahashi T. Inhibition of interleukin 2 by serum in healthy individuals and in patients with autoimmune disease. Int Arch Allergy Appl Immunol 1987; 84: 135–41
- Yamagata N, Kobayashi K, Kasama T, Fukushima T, Tabata M, Yoneya I, Shikama Y, Kaga S, Hashimoto M, Yoshida K, Sekine F, Negishi M, Ide H, Mori Y, Takahashi T. Multiple cytokine activities and loss of interleukin 2 inhibitor in synovial fluids of patients with rheumatoid arthritis. J Rheumatol 1988; 15: 1623–7
- Kobayashi K, Cohen S, Yoshida T. The characterization of the antigen-reactive T cell line mediating in vivo delayed type hypersensitivity established by antigen-induced interleukin 2. J Exp Pathol 1989; 4: 163–79
- Smith K A, Ruscetti F W. T cell growth factor and the culture of cloned functional T cells. Adv Immunol 1981; 31: 137–75
- Hardt C, Röllinghoff M, Pfizenmaier K, Mosmann H, Wagner H. Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo. J Exp Med 1981; 154: 262–74
- Male D, Lelchuk R, Curry S, Pryce G, Playfair J HL. Serum IL-2 inhibitor in mice. II. Molecular characteristics. Immunology 1985; 56: 119–25
- Ishizaka S, Tsuji T. IL-2 antibody production in lupus mice. Cell Immunol 1989; 118: 100–7
- Atkins M B, Gould J A, Allegretta M, Li J J, Dempsey R A, Rudders R A, Parkinson D R, Reichlin S, Mier J W. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 1986; 4: 1380–91
- Kolitz J E, Welte K, Wong G Y, Holloway K, Merluzzi V I, Engert A, Bradley E C, Konrad M, Polivka A, Gabrilove J L, Sykora K W, Miller G A, Fiedler W, Krown S, Oettgen H F, Mertelsmann R. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2. J Biol Response Mod 1987; 6: 412–29
- Panem S, Check I J, Henriksen D, Vilcek J. Antibodies to α-interferon in a patient with systemic lupus erythematosus. J Immunol 1982; 129: 1–3
- Svenson M, Poulsen L K, Fomsgaard A, Bendtzen K. IgG autoantibodies against interleukin 1α in sera of normal individuals. Scand J Immunol 1989; 29: 489–92
- Dinarello C A, Mier J W. Lymphokines. N Engl J Med 1987; 317: 940–5
- Dauphinee M J, Kipper S B, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981; 127: 2483–7
- Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin 2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69: 1388–92